Psychedelics
March 7, 2026
Skylar J. Gaughan, Jae Sevelius, Rafael Lancelotta et al.
Psychedelics have long histories of use in Indigenous communities for healing, spiritual, and ceremonial purposes. In contrast, Western psychedelic science has emerged through frameworks shaped by colonization, racism, and medicalization. These systems often marginalize and exclude the very communities most impacted by trauma, including transgender and gender-expansive (TGE) individuals,...
Journal of Psychedelic Studies
September 4, 2025
Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda et al.
4 citations
Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistance. Psilocybin-assisted therapy (PAT) shows promise in reducing depressive symptoms, but long-term effects are unknown. We aimed to determine the long-term safety and efficacy of PAT for MDD over a five-year follow-up period. Methods Individuals who...
Expert Review of Clinical Pharmacology
June 11, 2025
Victor Pablo Acero, Taylor A Flatt, Peter M. Gooch et al.
Psychedelic compounds are emerging treatments for depression, capable of producing rapid and lasting symptom reduction after 1-2 administrations in the context of psychotherapy - a stark contrast to traditional antidepressants. Despite promising outcomes, the mechanisms underlying psychedelics' reported antidepressant effects remain poorly understood and are often framed in fragmented ways....
International Journal of Transgender Health
March 19, 2025
Skylar J. Gaughan, Angie R. Wootton, Daphne Krantz et al.
6 citations
Background: While psychedelic medicines have increasingly been studied for their utility as an adjunct to psychotherapy, transgender and gender-expansive (TGE) individuals have rarely been the focus of psychedelic research. This study examines TGE people's naturalistic, non-clinical psychedelic experiences to explore how TGE people use psychedelics and how they describe relationships between...